• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

    Transitioning from Clinical Production to Commercial Manufacturing

    Clinical Trial Technology

    Regenerative Medicine: Overcoming the supply chain challenges

    The Future of the Pharmaceutical Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness

    Amgen Selects Location For R&D Facility

    Arctoris Opens Oxford R&D Facility

    Almac Group, Exostar Collaborate on IRT Experience

    Northwest Biotherapeutics Expands Management Team
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Amgen Selects Location For R&D Facility

    Catalent Launches Clinical Trial Planning Service

    CatSci Expands Capabilities with Lab Expansion

    PCI Pharma Services Invests in Tredegar, UK Site

    Avantor Boosts Biopharmaceutical Innovation in China
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Smart Tags on Pills Set to Improve Supply Chain Security and Patient Adherence

    Schreiner MediPharm, PragmatIC Form Partnership for Smart Pharma Labels

    Stevanato Group Begins Construction on TEC

    CSafe Global Expands Packaging Portfolio

    CSafe Global Opens Service Centers in Switzerland and Sweden
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness

    Amgen Selects Location For R&D Facility

    Arctoris Opens Oxford R&D Facility

    Almac Group, Exostar Collaborate on IRT Experience

    Charles River Provides Access to Cosmic Antibody Library
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pelican BioThermal Achieves ISO Accreditation

    PhRMA Appoints Federal Advocacy SVP

    CureVac Granted Mfg. Authorization for GMP Production Suite

    Metrics Completes Japanese Regulatory Inspection

    Samsung Biologics Achieves ISO27001 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Ajinomoto Bio-Pharma Services

    Vetter Pharma International GmbH

    Alcami

    Jubilant HollisterStier Contract Manufacturing & Services

    CCRM
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions, Inc.

    Flow Sciences, Inc.

    Baxter BioPharma Solutions

    Alcami

    Federal Equipment Company
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Regenerative Medicine: Overcoming the supply chain challenges

    Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.

    Regenerative Medicine: Overcoming the supply chain challenges
    Related CONTENT
    • Vineti Opens New Regional HQ in Maryland
    • The Orphan Promise
    • Risk-Based Monitoring
    • The 20th Annual Salary Survey
    • Sierra’s Momelotinib Granted FDA Fast Track Designation
    Rich Quelch, Global Head of Marketing, Origin11.20.19
    Regenerative medicine is one of modern science’s most exciting developments. Defined by the Medical Research Council, “regenerative medicine is an interdisciplinary field that seeks to develop the science and tools that can help repair or replace damaged or diseased human cells or tissues to restore normal function”.

    In the human body, the liver is the only organ capable of regenerating itself spontaneously—even after serious injury—but in the future, any part of the human body may be capable of doing so. Our own cells will also be able to treat and cure diseases and conditions of the blood and immune system, as well as restore the blood system after treatments for specific cancers.

    Once only imaginable in science fiction, the latest applications include engineered skin tissue to treat burn victims, custom-grown bones for implants and joint replacements, personalized dietary treatments using gut bacteria and just recently, the world’s first 3D vascularized engineered heart was created using a patient’s own cells and biological materials.

    As scientists’ understanding and the tools at their disposal become more advanced, the closer to the widespread commercialization of regenerative medicine the pharmaceutical industry finds itself.
    However, offering regenerative medicine therapies at scale requires one of the biggest shake-ups to the global pharmaceutical supply chain ever seen. Without it, the world risks missing out on the curative promises of this next-generation medical technology.

    Understanding the potential of regenerative medicine
    Regenerative medicine is one of, if not the most, exciting advancements in modern science which has far-reaching benefits for big pharma, healthcare systems and patient outcomes.

    Regenerative medicine is a “growth” industry in more than one sense of the word; as a sector, it’s growing from strength to strength. In fact, last year the global regenerative medicine market was worth $28 billion and it’s expected to grow to $81 billion by 2023.

    As a more efficient and less invasive alternative to transplanting cells or organs to replace damaged or lost tissue, established pharma companies alongside small biotech start-ups are racing to discover and bring to market medicine-based approaches that stimulate the body’s natural ability to repair itself.
    The cutting-edge innovations of regenerative medicine generally fall into three distinct categories:

    • Replenish
    • Replace
    • Rejuvenate

    Stem cells can generate vital growth factors to naturally reduce inflammation, increase muscle mass, repair joints, grow hair and boost the immune system, replenishing the body. Organ regeneration and 3D printing are replacing the reliance on the failing donor system and overcoming the issue of organ rejection. The root causes of aging are being better understood and delayed by using stem cells to rejuvenate the body.

    Marking a new era in healthcare and one which has the promise of addressing the needs of an aging population challenged by escalating chronic diseases, regenerative medicine is certainly a game-changer. Beyond more effective medical treatments that can be applied routinely despite age, comorbidities, or disease severity, it also has the potential to cure many of today’s “incurable” diseases and support healthcare systems to move towards a preventative model.

    Delivering regenerative medicine from lab to clinic
    Today, regenerative medicine is largely confined to a research environment. In fact, according to a recent report, there were 1,028 clinical trials for regenerative therapies taking place globally at the end of 2018.

    Regenerative medicine is poised to transform healthcare as we know it, offering potential cures for deadly diseases which before would require long-term treatment to manage. However, while billions are being spent on regenerative medicine research and clinical studies, little resource has, so far, been allocated to the management and delivery of innovative medical therapies at scale.

    Currently, the race appears to be on between smaller Medtech companies and large multi-national pharmaceutical companies to see who wins first-mover advantage in the regenerative medicine market. Today, many established pharmaceutical companies prefer to partner with Medtech startups to in-license products in early clinical development stages as opposed to conducting early development on their own which comes at a huge cost. This is a risk-reduction tactic, but it could mean big pharma misses the boat.

    The question remains unanswered as to whether a peer-to-peer collaborative model will prosper where Medtech companies—who are in some instances one step ahead of big pharma in terms of drug development—are happy to be a third-party provider to big pharma who have the budgets and networks to truly deliver the regenerative medicine revolution.

    Regulation is, and will continue to, play a hugely important role in delivering regenerative medicines from a lab setting to a clinical setting. Only recently, the FDA announced a new policy framework for the development of regenerative medicine products, taking into account the dynamic and fast-moving nature of the field.

    Ultimately, the government’s aim is to “protect patients from products that pose potential significant risks, while accelerating access to safe and effective new therapies” according to Former FDA Commissioner Dr. Scott Gottlieb. The FDA plans to achieve this over the coming years by driving stakeholder engagement with the developing regulatory framework in order to efficiently advance access to safe and effective regenerative medicine advanced therapies.

    However, so far, progress by the pharma industry in coming into compliance with FDA’s regulations for regenerative medicines has been slow, despite the grace period set by the FDA before it fully exercises enforcement fast approaching (ending in November 2020).

    In order to speed up the process of bringing novel medicines to market, the FDA is toying with the idea of fast-tracking products that are deemed low risk to patients if sponsors have engaged with the regulatory process and demonstrated responsibility by filing Investigational New Drug Applications (INDs).

    The FDA has also promised to strengthen its enforcement action against drug developers who are marketing unapproved products, prioritizing cases where the threat to patient health and safety is largest.
    For example, last November the FDA stepped in where a Californian business was selling stem cell products using umbilical cord blood for the treatment of arthritis and other conditions, despite this form of treatment not having FDA approval for that particular use. Several patients (at least 12) undergoing this treatment were hospitalized after developing infections of the bloodstream and joints, as well as abscesses along the spine and skull.

    In summary, one of the FDA’s central aims over the coming years is to drive stakeholder engagement with the developing regulatory framework for regenerative medicine advanced therapies in order to efficiently advance access to safe and effective new products.

    Establishing an efficient supply chain for regenerative medicine
    The promise of regenerative medicine requires an innovative look at the complete product lifecycle, including the development of an efficient distribution network.

    Once these novel drugs become mainstream, the entire healthcare ecosystem will have to adapt. Regulatory approval for any drug relies on it safely and successfully fulfilling its medical intent.  As such, information about supply chain management needs to be submitted to the regulator after the completion of phase three clinical trials, including packaging, labeling, storage and distribution.

    The clinical supply chains required to deliver these therapies are arguably the most complex the industry has seen so far, even more so than for biologic medicine. That’s because, unlike many mass-market drugs, regenerative medicine is either personalized or matched to a unique donor-recipient.

    The distribution of regenerative medicine therapies is further complicated by the fact they are also extremely sensitive to exogenous factors like time and temperature. Therefore, there are strict conditions under which these therapies must be transported and received.

    Advanced IT solutions and monitoring systems are being developed and employed to ensure end-to-end traceability across the pharma supply chain. These are giving clinicians access to view the progress of therapies and their distribution in real-time and allow users to automatically schedule or amend material collections in line with manufacturing capacity, helping to keep the supply chain as agile as possible and avoid costly wastage.

    The live tissues and cells which form the basis of regenerative medicine products are highly sensitive and some have a shelf life of no more than a few hours, making distribution a complex task. Therefore, materials need to be transported from the site of harvest to manufacturing facilities, and from manufacturing facilities to medical institutions under strictly controlled conditions, within certain time periods and temperatures, according to different cell and tissue requirements which can vary from product to product.

    Temperature-controlled logistics solutions are vital to ensure a safe, effective and financially viable supply chain network for these high-value shipments. Cryopreservation is one technique increasingly being used to deliver medicines at optimum temperature using vapor phase nitrogen, however, many clinical settings remain ill-equipped to handle such equipment.

    Onsite production is an alternative manufacturing arrangement, particularly for autologous products which are derived from a patient’s own cells. However, this throws up a number of compliance and infrastructure challenges, as the hospital would need to comply with a host of regulations including installing a licensed clean room which may not be possible given budget restrictions and limited space onsite.
    As a first-generation technology, stakeholders will have a greater tolerance for higher pricing, but only for a limited time period. By streamlining the currently very expensive manufacturing process and improving supply chain management, yields will automatically get larger and costs will slowly come down.

    While there are many challenges in the road ahead, 2019 certainly appears to be the start of regenerative medicine’s move to the big time. Just like big data and artificial intelligence is transforming the practice of medicine, regenerative medicine holds the promise of extending the body’s natural ability to replenish, replace and rejuvenate itself.

    If the global health industry can work collaboratively on overcoming the challenges presented by delivering safe and effective advanced therapies, a dramatic extension of the human healthspan is possible. We may even reach the point where no disease is considered “incurable”, transforming healthcare as we know it. 


    Rich Quelch is an experienced global marketer within the healthcare and pharmaceutical sector. He has led the development of the Origin brand, positioning it as a world-leading supplier of innovative and ground-breaking pharmaceutical packaging devices, as well as offering a unique supply chain model which is disrupting the pharma industry. 
    Related Searches
    • clinical development
    • Clinical Trials
    • capacity
    • it
    Suggested For You
    A Pharmaceutical Smörgåsbord A Pharmaceutical Smörgåsbord
    Biopharma Over 20 Years Biopharma Over 20 Years
    3P Bio Completes Tech Transfer 3P Bio Completes Tech Transfer
    CPhI Worldwide Celebrates 30 Years CPhI Worldwide Celebrates 30 Years
    Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future
    Cesca Therapeutics, HealthBanks Biotech Form Cell-Based CDMO JV Cesca Therapeutics, HealthBanks Biotech Form Cell-Based CDMO JV
    Astellas to Fund Boston-Area Cell and Gene Therapy Start-Up Astellas to Fund Boston-Area Cell and Gene Therapy Start-Up
    Quality Metrics Feedback Quality Metrics Feedback
    FDA Extends CRADA with CluePoints FDA Extends CRADA with CluePoints
    Leveraging Machine Learning and AI in Clinical Research Leveraging Machine Learning and AI in Clinical Research
    GenCure Reports Successful First Run of 80L Bioreactor GenCure Reports Successful First Run of 80L Bioreactor
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    22	ASTELLAS 22 ASTELLAS
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?

    Related Features

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    • Biologics, Proteins, Vaccines | Facilities
      Fujifilm Eyes Being ‘Total Healthcare Company’

      Fujifilm Eyes Being ‘Total Healthcare Company’

      Invests nearly $900 million to acquire Biogen’s manufacturing hub in Denmark.
      Tim Wright, Editor, Contract Pharma 10.15.19


    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19

    • Biologics, Proteins, Vaccines
      The ADC Market is Fast Evolving

      The ADC Market is Fast Evolving

      Applications of ADCs are widening and improvements in the manufacturing process meet industry requirements.
      Charlie Johnson, CEO, ADC Bio 06.13.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Are Biotech Companies Strong Investments?

      Are Biotech Companies Strong Investments?

      Biotech capital raised via IPO has increased dramatically over the past couple of years.
      Jason Monteleone , CEO, Clinipace 05.07.19


    • Biologics, Proteins, Vaccines
      The Coming Revolution of Personalized Medicine

      The Coming Revolution of Personalized Medicine

      Cell and gene therapy is creating a momentous shift in the pharma landscape and reshaping the future of medicine.
      Tommy Fanning, Global Head Biopharmaceuticals, IDA Ireland 05.07.19

    • Biologics, Proteins, Vaccines | Parenterals
      Seasonal Vaccine Manufacturing

      Seasonal Vaccine Manufacturing

      Experience can increase speed and assurance of delivery.
      Wendy Saffell-Clemmer, Lead Scientist, R&D, Senior Director Baxter Pharmaceuticals & Baxter Biopharma Solutions 05.07.19

    • Biologics, Proteins, Vaccines | Process Validation
      Process Validation in Biologics Development

      Process Validation in Biologics Development

      Strategies for successful process validation in the wake of faster approval timelines.
      Victor Vinci and Claudia Berdugo-Davis, Catalent Biologics 05.07.19


    • Biologics, Proteins, Vaccines
      The Biopharma Future

      The Biopharma Future

      A look at current trends driving volume reductions in biopharmaceutical manufacturing and keys for successful outsourcing partnerships.
      Karl Pinto and Dave Cunningham, Goodwin Biotechnology 05.07.19

    • Biologics, Proteins, Vaccines
      Immuno-oncology Safety Assessment

      Immuno-oncology Safety Assessment

      Taking the brakes off the immune system with checkpoint inhibitor antibodies.
      Dr. Kirsty Harper, Head of Biologics, Envigo 03.06.19

    • Biologics, Proteins, Vaccines
      Preparing For Your CDMO Selection Process

      Preparing For Your CDMO Selection Process

      Five questions that must be answered before starting your CDMO search.
      Ajinomoto Bio-Pharma Services 03.06.19

    • Biologics, Proteins, Vaccines
      Integrating Antibody Purification and Conjugation

      Integrating Antibody Purification and Conjugation

      An advanced manufacturing technique for transforming ADC production efficiencies
      Charlie Johnson, CEO, ADC Bio 10.10.18

    • Biologics, Proteins, Vaccines | Injectables
      Next-Gen Biologics Packaging & Delivery

      Next-Gen Biologics Packaging & Delivery

      As the frontier of drug innovation evolves, so must the design of packaging and delivery systems.
      09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    Breaking News
    • Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    • Amgen Selects Location For R&D Facility
    • Arctoris Opens Oxford R&D Facility
    • Almac Group, Exostar Collaborate on IRT Experience
    • Northwest Biotherapeutics Expands Management Team
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    • Transitioning from Clinical Production to Commercial Manufacturing
    • Clinical Trial Technology
    • Regenerative Medicine: Overcoming the supply chain challenges
    • The Future of the Pharmaceutical Supply Chain
    • Challenges and Opportunities in Vaccines Drug Development
    • Managing Partnerships: Sponsors & CDMOs
    • Towards Sunset or a New Dawn?
    • Biopharma Over 20 Years
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs World's First Single-Use Duodenoscope
    Dr. Stephen Hahn Confirmed as New FDA Leader
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    Amgen Selects Location For R&D Facility
    Arctoris Opens Oxford R&D Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Cosmetic Assessments Revealed at CIR Panel
    T-Boz Launches CBD Line
    DRF and Flowerkist Develop CBD Range
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    LogoJet Opens Bogota, Colombia Office
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.